The Report Surveys 75 Life Sciences Leaders to Uncover What is Standing in the Way of Stronger Patient Engagement
Lirio, the first behavioral science and agentic AI platform designed to help people live healthier lives, released a report based on surveys with more than 75 executives from life sciences companies. The report found that many in-house commercialization and personalization efforts are failing to improve patient engagement.
Health Technology Insights: Rocket Doctor AI Partners to Boost AI Clinical Support in Alberta
The study, titled “From Mass Messaging to N-of-1,” was conducted by healthcare consultancy Sage Growth Partners to understand why patient engagement strategies often fall short and to explore where AI could help life sciences companies improve outcomes.
Recent changes in regulations for direct-to-consumer pharmaceutical advertising, along with the launch of the federal DTC drug pricing website, are reshaping how companies communicate with patients. Traditional outreach methods have steadily lost effectiveness, resulting in persistently low patient engagement. Studies show that nearly half of patients do not take their medications as prescribed, highlighting the extent of the challenge.
As patients increasingly expect personalized experiences, life sciences companies are turning to direct-to-consumer strategies. Yet almost all surveyed executives said patient engagement remains a persistent struggle. More than 70 percent identified maintaining engagement in clinical trials and ensuring medication adherence after commercialization as their top challenges. Poor adherence contributes to $100 billion in avoidable healthcare costs annually and 125,000 preventable deaths each year, underlining the gap between DTC ambitions and actual patient impact.
Health Technology Insights: Adagio Medical Adds Executives to Boost ULTC Launch
The report also revealed that the industry has been slow to adopt innovative personalization methods. Only half of companies use digital health technologies to engage patients during clinical trials and after launch, and fewer than three percent have partnered with vendors specializing in patient engagement.
“Although the life sciences industry has made major advances in targeted therapies and data-driven care, many companies are still not effectively connecting with patients,” said Dr. Amy Bucher, Chief Behavioral Officer at Lirio. “As organizations explore direct-to-patient and direct-to-consumer strategies, they must understand the cognitive, social, and environmental factors that influence health behaviors and pair that insight with the right technology to drive meaningful change.”
Following the report, Lirio introduced Precision Nudging for Life Sciences, a solution designed to enhance patient engagement. This initiative aligns with Lirio’s recent signing of the Centers for Medicare & Medicaid Services Health Technology Ecosystem Pledge and underscores the company’s commitment to building smarter, more personalized healthcare experiences in collaboration with healthcare organizations.
Health Technology Insights: ACCO Brands to Acquire EPOS
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
